Since POETIC's inception, two first-in-child clinical trials have been conducted increasing early access to novel molecularly targeted agents for treatment of children and adolescents with refractory malignancies after completion of adult Phase I studies. One of the studies resulted in evidence of clinical benefit in patients with tumors of the central nervous system using a novel agent targeting the epidermal growth factor receptor, cetuximab. These findings have provided the scientific rationale for a Phase II study targeting high grade central nervous system tumors, which is on-going.
Sponsor: Amgen
Protocol: POE14-01
Principal investigator: Jessica Boklan, MD
Site: Phoenix Children's Hospital
Estimated accrual years: 2.0
Read more about this trial at ClinicalTrials.gov
Sponsor: Genentech
Protocol: N/A
Principal investigator: N/A
Site: N/A
Estimated accrual years: 2.0
Read more about this trial at ClinicalTrials.gov
Sponsor: Genentech
Protocol: GO40871
Estimated accrual years: 5 years (in 3 phases)
Read more about this trial at ClinicalTrials.gov
Sponsor: Puma
Protocol: POE16-01
Principal investigator: Tanya Trippett, MD
Site: Memorial Sloan Kettering Cancer Center
Estimated accrual years: 1.0 (Phase I); 1.5 (Phase II)
Read more about this trial at ClinicalTrials.gov
Sponsor: N/A
Protocol: POE10-01
Principal investigator: Tanya Trippett, MD
Site: Memorial Sloan Kettering Cancer Center
Actual accrual years: 2.8
Read more about this trial at ClinicalTrials.gov
Sponsor: N/A
Protocol: POE10-02
Principal investigator: Tanya Trippett, MD
Site: Memorial Sloan Kettering Cancer Center
Actual accrual years: 2.0 (Phase I); 2.4 (Phase II)
Read more about this trial at ClinicalTrials.gov
Sponsor: N/A
Protocol: POE08-01
Principal investigator: Ira Dunkel, MD
Site: Memorial Sloan Kettering Cancer Center
Actual accrual years: 2.0
Read more about this trial at ClinicalTrials.gov
Sponsor: N/A
Protocol: POE09-01
Principal investigator: Mark Kieran, MD
Site: Dana-Farber
Actual accrual years: 2.1
Read more about this trial at ClinicalTrials.gov
Sponsor: N/A
Protocol: POE10-03
Principal investigator: Todd Cooper, MD
Site: Children's Healthcare of Atlanta
Actual accrual years: 2.0
Read more about this trial at ClinicalTrials.gov
Sponsor: Genentech
Protocol: N/A
Principal investigator: N/A
Site: N/A
Estimated accrual years: 1.0
Programs
Return to Top
Industry Partners
Family and Patients